GENAISSANCE PHARMACEUTICALS AND IPSOGEN ANNOUNCE CANCER BIOMARKER RESEARCH AGREEMENTS

Privately-held Ipsogen SAS and Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that they have signed collaboration agreements with two global pharmaceutical companies. These collaborations will focus on identifying biomarkers that may drive the response to anti-cancer drugs. Under the terms of the agreements, Ipsogen will collect samples from clinical trials and will perform sample processing and pathology analysis, while Genaissance will perform genotyping and data analysis.

Yahoo News (http://biz.yahoo.com/prnews/050912/nym021.html?.v=24)